Abstract
Some mechanism-based inhibitors cause irreversible inhibition by forming a metabolic intermediate complex (MIC) with cytochrome P450. In the present study, 54 molecules (substrates of CYP3A and amine-containing compounds that are not known substrates of CYP3A) were spectrophotometrically assessed for their propensity to cause MIC formation with recombinant CYP3A4 (+b5). Comparisons of common physicochemical properties showed that mean (±S.D.) mol. wt. of MIC-forming compounds was significantly greater than mean mol. wt. of non-MIC-forming compounds, 472 (±173) versus 307 (±137), respectively. Computational pharmacophores, logistic regression, and recursive partitioning (RP) approaches were applied to predict MIC formation from molecular structure and to generate a quantitative structure activity relationship. A pharmacophore built with SKF-525A (2-diethylaminoethyl 2:2-diphenylvalerate hydrochloride), erythromycin, amprenavir, and norverapamil indicated that four hydrophobic features and a hydrogen bond acceptor were important for these MIC-forming compounds. Two different RP methods using either simple descriptors or 2D augmented atom descriptors indicated that hydro-phobic and hydrogen bond acceptor features were required for MIC formation. Both of these RP methods correctly predicted the MIC formation status with CYP3A4 for 10 of 12 literature molecules in an independent test set. Logistic multiple regression and a third classification tree model predicted 11 of 12 molecules correctly. Both models possessed a hydrogen bond acceptor and represent an approach for predicting CYP3A4 MIC formation that can be improved using more data and molecular descriptors. The preliminary pharmacophores provide structural insights that complement those for CYP3A4 inhibitors and substrates.
Footnotes
-
This work was supported by grants from the National Institutes of Health (Grants AG13718 to S.D.H. and GM74217 to S.D.H.) and the U.S. Food and Drug Administration (Grant FD-T-001756-01 to S.D.H.).
-
doi:10.1124/dmd.106.014613.
-
ABBREVIATIONS: P450, cytochrome P450; MIC, metabolic intermediate complex; QSAR, quantitative structure activity relationship; SKF-525A, 2-diethylaminoethyl 2:2-diphenylvalerate hydrochloride; MDMA, methylenedioxymethamphetamine; MDE, methylenedioxyethylamphetamine; MBDB, 2-methylamino-1-(3,4-methylenedioxyphenyl)butane; CSAR, classification structure activity relationship; glm, generalized linearized model; DDB, dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′decarboxylate.
-
↵ The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.
- Received December 28, 2006.
- Accepted May 24, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|